Clinical Trials Logo

Immune Thrombocytopenia clinical trials

View clinical trials related to Immune Thrombocytopenia.

Filter by:

NCT ID: NCT05281068 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicenter study to compare the efficacy and safety of combination of iguratimod and danazol versus danazol for the treatment of adults with steroid-resistant/ relapse immune thrombocytopenia (ITP).

NCT ID: NCT05279872 Completed - Clinical trials for Immune Thrombocytopenia

A Study of Zanubrutinib in Patients With ITP

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Zanubrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

NCT ID: NCT05214391 Recruiting - Clinical trials for Immune Thrombocytopenia

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.

NCT ID: NCT05152238 Recruiting - Clinical trials for Immune Thrombocytopenia

ITP Registry and Accompanying Biospecimen Collection

ITP-Registry
Start date: November 29, 2021
Phase:
Study type: Observational [Patient Registry]

The objective of this ITP registry is to collect clinical information, including biosampling, from consenting patients with a variety of ITPs at different points in the course of their disease.

NCT ID: NCT05124028 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

A Study of Orelabrutinib in Patients With ITP

Start date: December 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

NCT ID: NCT05116423 Recruiting - Clinical trials for Immune Thrombocytopenia

Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia

Start date: November 10, 2021
Phase:
Study type: Observational

This study developed the first prediction model for risk of critical ITP bleeds for ITP inpatients using a novel machine learning algorithm. This model has been implemented as a web-based model so that clinicians can obtain the estimated probability of critical ITP bleeds for ITP inpatients. The objective of this study is to prospectively and externally validate the risk of critical ITP bleeds in newly admitted ITP patients.

NCT ID: NCT05095896 Completed - Clinical trials for Immune Thrombocytopenia

The Serum Lipid Profiles in ITP: a Retrospective Study

Start date: January 1, 2018
Phase:
Study type: Observational

The project was retrospectively undertaking by Qilu Hospital of Shandong University in China. In order to investigate the correlations between platelet indices, serum lipids and bleeding symptoms in ITP.

NCT ID: NCT05046327 Withdrawn - Clinical trials for Immune Thrombocytopenia

Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months

Start date: October 14, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of avatrombopag in subjects with a confirmed diagnosis of primary ITP (≤6 months duration) over 26 weeks of treatment, and also evaluate the incidence of ITP remission.

NCT ID: NCT05023915 Recruiting - Clinical trials for Immune Thrombocytopenia

A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

Start date: August 21, 2021
Phase: Phase 2
Study type: Interventional

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

NCT ID: NCT05020288 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

BTK participates in a variety of signal transduction of innate and adaptive immunity, and has an important role in cell proliferation, differentiation and apoptosis. The impact of BTK inhibitors on hematological malignancies and autoimmune diseases has been well studied. This project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of the selective BTK inhibitor Orelabrutinib in the management of refractory ITP.